S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Modern Day Options Trading For Beginners! (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Modern Day Options Trading For Beginners! (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Modern Day Options Trading For Beginners! (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Modern Day Options Trading For Beginners! (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
TSE:MDNA

Medicenna Therapeutics - MDNA Stock Forecast, Price & News

C$0.88
+0.10 (+12.82%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
C$0.80
C$0.88
50-Day Range
C$0.72
C$1.05
52-Week Range
C$0.54
C$2.38
Volume
22,950 shs
Average Volume
25,049 shs
Market Capitalization
C$61.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$6.57

MDNA stock logo

About Medicenna Therapeutics (TSE:MDNA) Stock

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

Medicenna Therapeutics Earnings Preview
5 Stocks to Buy Immediately
America’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. pixel
Earnings Preview For Medicenna Therapeutics
5 Stocks to Buy Immediately
America’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. pixel
CIG, GRTX and MDNA among pre market gainers
See More Headlines
Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$6.57
High Stock Price Forecast
C$14.00
Low Stock Price Forecast
C$2.00
Forecasted Upside/Downside
+646.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
C$-9,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.77 per share
Book Value
C$0.48 per share

Miscellaneous

Free Float
N/A
Market Cap
C$61.28 million
Optionable
Not Optionable
Beta
0.53

Key Executives

  • Dr. Fahar Merchant Ph.D. (Age 65)
    Founder, Chairman, Pres & CEO
    Comp: $462.15k
  • Ms. Rosemina Merchant B.Sc. (Age 65)
    M.E.Sc, Founder, Chief Devel. Officer & Director
    Comp: $370.62k
  • Ms. Elizabeth Williams C.A. (Age 44)
    CPA, CA, CPA, CFO & Corp. Sec.
    Comp: $311k
  • Dr. Martin Bexon M.D.
    MBBS, Acting Chief Medical Officer & Head of Clinical Devel.
  • Dr. Samuel R. Denmeade M.D.
    Scientific Advisor













MDNA Stock - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDNA shares.
View MDNA analyst ratings
or view top-rated stocks.

What is Medicenna Therapeutics' stock price forecast for 2023?

6 brokers have issued 1 year target prices for Medicenna Therapeutics' shares. Their MDNA share price forecasts range from C$2.00 to C$14.00. On average, they predict the company's stock price to reach C$6.57 in the next year. This suggests a possible upside of 646.8% from the stock's current price.
View analysts price targets for MDNA
or view top-rated stocks among Wall Street analysts.

How have MDNA shares performed in 2023?

Medicenna Therapeutics' stock was trading at C$0.64 at the start of the year. Since then, MDNA stock has increased by 37.5% and is now trading at C$0.88.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Medicenna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO).

What is Medicenna Therapeutics' stock symbol?

Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA."

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Medicenna Therapeutics' stock price today?

One share of MDNA stock can currently be purchased for approximately C$0.88.

How much money does Medicenna Therapeutics make?

Medicenna Therapeutics (TSE:MDNA) has a market capitalization of C$61.28 million. The company earns C$-9,400,000.00 in net income (profit) each year or C($0.16) on an earnings per share basis.

How can I contact Medicenna Therapeutics?

Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The official website for the company is www.medicenna.com. The company can be reached via phone at +1-403-6807898.

This page (TSE:MDNA) was last updated on 4/1/2023 by MarketBeat.com Staff